Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Home-use 308-nm LED Phototherapy plus Topical Ruxolitinib for Non-Facial Vitiligo
ChiCTR2600129366Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ruxolitinib in Vitiligo (2 arms), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Improvement rate of the non-facial Vitiligo Area Scoring Index at Week 24 compared with baseline. Started Aug 2026; status: recruiting.
02
Drugs
03
Conditions
Vitiligo
Beyond the preview
Go deeper on ChiCTR2600129366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129366.